Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse

(2013) T. Lange et al.   HAEMATOLOGICA

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

(2012) B. L. Scott et al.   BLOOD

Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors

(2012) V. Gupta et al.   BLOOD

Risk models predicting survival after reduced-intensity transplantation for myelofibrosis

(2012) Haefaa Alchalby et al.   BRITISH JOURNAL OF HAEMATOLOGY

Inheritance of the chronic myeloproliferative neoplasms. A systematic review

(2012) A Ranjan et al.   CLINICAL GENETICS

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?

(2011) John T. Horan et al.   JOURNAL OF CLINICAL ONCOLOGY

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis

(2011) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study

(2010) W A Stewart et al.   BONE MARROW TRANSPLANTATION

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

(2010) D Caramazza et al.   LEUKEMIA

Outcome of Transplantation for Myelofibrosis

(2009) Karen K. Ballen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

(2009) N. Kroger et al.   BLOOD

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

(2009) N. Kroger et al.   BLOOD

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

(2009) F. Passamonti et al.   BLOOD

A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis

(2009) V Gupta et al.   BONE MARROW TRANSPLANTATION

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

(2009) A Bacigalupo et al.   BONE MARROW TRANSPLANTATION

Graft-versus-host disease

(2009) James LM Ferrara et al.   LANCET

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden

(2008) O. Landgren et al.   BLOOD

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD